세계의 임신성 당뇨 시장 보고서(2025년)

Gestational Diabetes Global Market Report 2025

US $ 4,490 ￦ 6,301,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,108,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,914,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

임신성 당뇨 시장 규모는 향후 몇 년 동안 강력한 성장을 보일 것으로 예상되며, 2029년에는 9.0%의 연평균 복합 성장률(CAGR)로 129억 달러에 달할 것으로 예측됩니다. 예측 기간 동안 예상되는 성장은 비만 유병률 증가, 클라우드 기반 프로젝트 솔루션의 채택 확대, 관련 기기 및 용도 사용 증가 등 다양한 요인에 의해 발생할 것으로 예측됩니다. 또한, 건강에 해로운 생활습관 선택으로 인한 당뇨병 환자의 급증, 공중보건에 대한 인식 증가, 당뇨병 발병률의 상승도 큰 요인입니다. 이 기간 동안 예상되는 주요 동향으로는 디지털 당뇨병 관리 앱의 출현, 폐쇄 루프 제어 시스템, 당뇨병 관리 기술의 발전, 효소 혁신, 기타 첨단 의료 발전 등이 있습니다.

비만 유병률 증가는 향후 임신성 당뇨 시장의 성장을 견인할 것으로 예측됩니다. 비만은 체질량지수(BMI)가 30 이상인 개인을 의미하며, 체지방이 과도하게 축적되어 건강에 심각한 위험을 초래할 수 있는 상태를 말합니다. 비만 증가는 좌식 생활습관, 고칼로리 가공식품 섭취 증가, 유전적 소인, 건강한 음식과 운동 옵션에 대한 접근성 제한 등의 요인에 의해 영향을 받습니다. 인슐린 저항성 및 임신 중 과도한 체중 증가의 위험을 증가시켜 산모와 태아 모두에게 합병증을 유발할 수 있습니다. 예를 들어, 스위스에 본부를 둔 정부 간 기구인 세계보건기구(WHO)는 2024년 3월, 2022년에는 전 세계 인구의 약 8명 중 1명이 비만과 함께 생활하고 있다고 보고했습니다. 여기에는 과체중으로 분류되는 18세 이상 성인 25억 명이 포함되며, 이 중 8억 9,000만 명이 비만과 함께 살고 있습니다. 성인 중 43%가 과체중, 16%가 비만인 것으로 나타났습니다. 또한 5세 미만 어린이 중 3,700만 명이 과체중이고, 5세에서 19세 사이의 어린이 및 청소년 중 3억 9,000만 명 이상이 과체중이며, 그 중 1억 6,000만 명이 비만을 앓고 있었습니다. 결과적으로 비만 인구 증가가 임신성 당뇨 시장의 성장을 견인하고 있습니다.

임신성 당뇨 시장의 주요 기업들은 진단 키트와 같은 첨단 제품 시장 개척에 주력하고 있으며, 증상을 조기에 발견할 수 있는 빠르고 정확하며 편리한 방법을 제공합니다. 임신성 당뇨 진단 키트는 임산부의 혈당을 측정하고 내당능 이상을 감지하는 데 사용되는 의료 도구로 증상을 조기에 발견하고 관리하는 데 도움이 됩니다. 예를 들어, 2024년 8월 오스트리아에 본사를 둔 생명공학 기업 DirectSens GmbH는 XpressGT RUO 키트를 발표했습니다. 이 진단 키트는 임신성 당뇨, 자궁내막증, 인슐린 저항성, 간질환을 감지하도록 설계되었습니다. 이 키트는 정맥혈의 2-하이드록시부티르산(2-HB) 수치를 측정하며, 2-HB 수치의 상승은 인슐린 저항성을 포함한 다양한 내분비 및 비만 관련 질환과 연관된 환원 스트레스 증가와 관련이 있습니다. 이 키트는 모든 임상 분석 장비와 호환되며, 단 8분 만에 결과를 얻을 수 있어 빠르고 효율적인 진단 솔루션을 제공합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나바이러스 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계 임신성 당뇨 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업 분석
• 세계의 임신성 당뇨 시장 : 성장률 분석
• 세계의 임신성 당뇨 시장 실적 : 규모와 성장, 2019-2024
• 세계의 임신성 당뇨 시장 예측 : 규모와 성장, 2024-2029, 2034F
• 세계 임신성 당뇨 전체 시장(TAM)

제6장 시장 세분화

• 세계의 임신성 당뇨 시장 : 유형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• Type A1
• Type A2
• 기타 유형
• 세계의 임신성 당뇨 시장 : 치료별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 모니터링
• 약물 치료
• 비약물 치료
• 세계의 임신성 당뇨 시장 : 관리별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 경구
• 정맥내
• 기타 관리
• 세계의 임신성 당뇨 시장 : 최종사용자별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 병원
• 클리닉
• 가정치료 환경
• 진단센터
• 세계의 임신성 당뇨 시장 : Type A1별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 식사 제한 임신성 당뇨
• 운동 제어 임신성 당뇨
• 세계의 임신성 당뇨 시장 : Type A2별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 인슐린 제어 임신성 당뇨
• 경구약 관리 임신성 당뇨
• 세계의 임신성 당뇨 시장 : 기타 유형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 임신전 당뇨병
• 합병증을 동반한 임신성 당뇨

제7장 지역별/국가별 분석

• 세계의 임신성 당뇨 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 세계의 임신성 당뇨 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

• 임신성 당뇨 시장 : 경쟁 구도
• 임신성 당뇨 시장 : 기업 개요
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis

제31장 기타 주요 기업 및 혁신 기업

• Becton, Dickinson and Company
• Boehringer Ingelheim GmbH
• Dexcom Inc
• Biocon Limited
• LifeScan Inc
• Ascensia Diabetes Care Holdings AG
• Trividia Health Inc.
• Nipro Diagnostics, Inc.
• Sernova Corp.
• ZyVersa Therapeutics, Inc.
• Peptron Inc.
• Roche Diabetes Care
• DiabetOmics Inc
• Merck & Co. Inc.
• Medtronic plc

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

• 임신성 당뇨 시장(2029년) : 새로운 기회를 제공하는 국가
• 임신성 당뇨 시장(2029년) : 새로운 기회를 제공하는 부문
• 임신성 당뇨 시장(2029년) : 성장 전략
  • 시장 동향에 근거한 전략
  • 경쟁 전략

제36장 부록

LSH

영문 목차

영문목차

Gestational diabetes is a type of diabetes that arises during pregnancy when the body fails to produce enough insulin to adequately regulate blood sugar levels. This condition usually emerges in the second or third trimester and can occur in women without a prior history of diabetes. Gestational diabetes poses risks to both the mother and the baby, including high birth weight, premature delivery, and an increased likelihood of developing type 2 diabetes later in life for both. Management typically involves adjustments to diet, regular exercise, blood sugar monitoring, and, if necessary, insulin therapy to support a healthy pregnancy and childbirth.

Gestational diabetes is categorized into several types, including Type A1, Type A2, and other forms. Type A1 refers to gestational diabetes mellitus (GDM) that develops during pregnancy due to insufficient insulin production to meet the increased demands of this period. Treatment strategies often include blood sugar monitoring, medication, and lifestyle interventions, which may be delivered orally, intravenously, or through other methods. These interventions are commonly implemented in hospitals, clinics, home care settings, and diagnostic centers.

The gestational diabetes market research report is one of a series of new reports from The Business Research Company that provides gestational diabetes market statistics, including gestational diabetes industry global market size, regional shares, competitors with gestational diabetes market share, detailed gestational diabetes market segments, market trends, and opportunities, and any further data you may need to thrive in the gestational diabetes industry. This gestational diabetes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The gestational diabetes market size has grown strongly in recent years. It will grow from $8.37 billion in 2024 to $9.14 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth during the historical period can be attributed to various factors, such as the increasing prevalence of diabetes, advancements in blood glucose measurement accuracy, a rise in the number of insurance providers, and a growing population of individuals with diabetes. Furthermore, the expanding diabetic population has played a significant role in driving this growth.

The gestational diabetes market size is expected to see strong growth in the next few years. It will grow to $12.90 billion in 2029 at a compound annual growth rate (CAGR) of 9.0%. The growth projected for the forecast period is driven by various factors, including the increasing prevalence of obesity, greater adoption of cloud-based project solutions, and the rising use of related devices and applications. Additionally, the surge in diabetes cases due to unhealthy lifestyle choices, heightened public health awareness, and escalating diabetes rates are significant contributors. Key trends anticipated during this period include the emergence of digital diabetes management apps, closed-loop control systems, advancements in diabetes management technologies, enzymatic innovations, and other cutting-edge medical advancements.

The growing prevalence of obesity is expected to drive the expansion of the gestational diabetes market in the future. Obesity refers to individuals with a body mass index (BMI) of 30 or higher, indicating excessive body fat that can lead to significant health risks. The rise in obesity is influenced by factors such as sedentary lifestyles, the increased intake of high-calorie processed foods, genetic predispositions, and limited access to healthy food and exercise options. Gestational diabetes treatment is particularly important for the obese population, as their increased risk of insulin resistance and excessive weight gain during pregnancy can cause complications for both the mother and baby if left untreated. For example, in March 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental agency, reported that approximately 1 in 8 people worldwide were living with obesity in 2022. This includes 2.5 billion adults aged 18 and older classified as overweight, of which 890 million were living with obesity. Among adults, 43% were overweight, and 16% were obese. Additionally, 37 million children under 5 years old were overweight, and more than 390 million children and adolescents aged 5 to 19 years were overweight, including 160 million living with obesity. As a result, the increasing obese population is driving the growth of the gestational diabetes market.

Leading companies in the gestational diabetes market are focusing on the development of advanced products, such as diagnostic kits, to offer quick, accurate, and convenient methods for early detection of the condition. A diagnostic kit for gestational diabetes is a medical tool used to measure blood glucose levels and detect abnormal glucose tolerance in pregnant women, helping in the early identification and management of the condition. For example, in August 2024, DirectSens GmbH, a biotechnology company based in Austria, introduced the XpressGT RUO kit. This diagnostic kit is designed to detect gestational diabetes, endometriosis, insulin resistance, and liver disease. It measures 2-hydroxybutyrate (2-HB) levels in venous blood, a substance naturally produced by the liver during its normal functions. Elevated 2-HB levels are linked to increased reductive stress, which is associated with various endocrine and obesity-related disorders, including insulin resistance. The kit is compatible with any clinical analyzer and provides results in just 8 minutes, offering a fast and efficient diagnostic solution.

In April 2024, Digostics, a diabetes home-testing provider based in the UK, partnered with AgaMatrix Europe to advance gestational diabetes screening. This collaboration grants AgaMatrix exclusive rights to distribute Digostics' home oral glucose tolerance testing (OGTT) service, GTT@home, to the UK National Health Service (NHS). By utilizing its strong connections and customer base within NHS maternity services, along with its extensive expertise in gestational diabetes monitoring, AgaMatrix aims to accelerate the introduction of GTT@home in the UK market. AgaMatrix Europe is a UK-based company specializing in the production of blood glucose monitoring solutions.

Major players in the gestational diabetes market are Sanofi S.A., AstraZeneca plc, Abbott Laboratories, Eli Lilly and Company, Novo Nordisk A/S, Becton, Dickinson and Company, Boehringer Ingelheim GmbH, Dexcom Inc, Biocon Limited, LifeScan Inc, Ascensia Diabetes Care Holdings AG, Trividia Health Inc., Nipro Diagnostics, Inc., Sernova Corp., ZyVersa Therapeutics, Inc., Peptron Inc., Roche Diabetes Care, DiabetOmics Inc, Merck & Co. Inc., Medtronic plc.

North America was the largest region in the gestational diabetes market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gestational diabetes report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the gestational diabetes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gestational diabetes market consists of revenues earned by entities by providing services such as nutritional counseling, medication management, telemedicine services, lifestyle and exercise guidance. The market value includes the value of related goods sold by the service provider or included within the service offering. The gestational diabetes market also includes sales of metformin, glyburide, and insulin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gestational Diabetes Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gestational diabetes market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gestational diabetes ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gestational diabetes market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Types: Type A1; Type A2; Other Types
• 2) By Treatment: Monitoring; Drug Treatment; Non-pharmacological treatment
• 3) By Administration: Oral; Intravenous; Other Administrations
• 4) By End User: Hospitals; Clinics; Home Care Settings; Diagnostic Centers
• Subsegments:
• 1) By Type A1: Diet-Controlled Gestational Diabetes; Exercise-Controlled Gestational Diabetes
• 2) By Type A2: Insulin-Controlled Gestational Diabetes; Oral Medication-Controlled Gestational Diabetes
• 3) By Other Types: Pre-Gestational Diabetes; Gestational Diabetes With Complications
• Companies Mentioned: Sanofi S.A.; AstraZeneca plc; Abbott Laboratories; Eli Lilly and Company; Novo Nordisk A/S
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Gestational Diabetes Market Characteristics

3. Gestational Diabetes Market Trends And Strategies

4. Gestational Diabetes Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Gestational Diabetes Growth Analysis And Strategic Analysis Framework

• 5.1. Global Gestational Diabetes PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Gestational Diabetes Market Growth Rate Analysis
• 5.4. Global Gestational Diabetes Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Gestational Diabetes Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Gestational Diabetes Total Addressable Market (TAM)

6. Gestational Diabetes Market Segmentation

• 6.1. Global Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Type A1
• Type A2
• Other Types
• 6.2. Global Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monitoring
• Drug Treatment
• Non-pharmacological treatment
• 6.3. Global Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous
• Other Administrations
• 6.4. Global Gestational Diabetes Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Home Care Settings
• Diagnostic Centers
• 6.5. Global Gestational Diabetes Market, Sub-Segmentation Of Type A1, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diet-Controlled Gestational Diabetes
• Exercise-Controlled Gestational Diabetes
• 6.6. Global Gestational Diabetes Market, Sub-Segmentation Of Type A2, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Insulin-Controlled Gestational Diabetes
• Oral Medication-Controlled Gestational Diabetes
• 6.7. Global Gestational Diabetes Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pre-Gestational Diabetes
• Gestational Diabetes With Complications

7. Gestational Diabetes Market Regional And Country Analysis

• 7.1. Global Gestational Diabetes Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Gestational Diabetes Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Gestational Diabetes Market

• 8.1. Asia-Pacific Gestational Diabetes Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Gestational Diabetes Market

• 9.1. China Gestational Diabetes Market Overview
• 9.2. China Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Gestational Diabetes Market

• 10.1. India Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Gestational Diabetes Market

• 11.1. Japan Gestational Diabetes Market Overview
• 11.2. Japan Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Gestational Diabetes Market

• 12.1. Australia Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Gestational Diabetes Market

• 13.1. Indonesia Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Gestational Diabetes Market

• 14.1. South Korea Gestational Diabetes Market Overview
• 14.2. South Korea Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Gestational Diabetes Market

• 15.1. Western Europe Gestational Diabetes Market Overview
• 15.2. Western Europe Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Gestational Diabetes Market

• 16.1. UK Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Gestational Diabetes Market

• 17.1. Germany Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Gestational Diabetes Market

• 18.1. France Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Gestational Diabetes Market

• 19.1. Italy Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Gestational Diabetes Market

• 20.1. Spain Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Gestational Diabetes Market

• 21.1. Eastern Europe Gestational Diabetes Market Overview
• 21.2. Eastern Europe Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Gestational Diabetes Market

• 22.1. Russia Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Gestational Diabetes Market

• 23.1. North America Gestational Diabetes Market Overview
• 23.2. North America Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Gestational Diabetes Market

• 24.1. USA Gestational Diabetes Market Overview
• 24.2. USA Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Gestational Diabetes Market

• 25.1. Canada Gestational Diabetes Market Overview
• 25.2. Canada Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Gestational Diabetes Market

• 26.1. South America Gestational Diabetes Market Overview
• 26.2. South America Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Gestational Diabetes Market

• 27.1. Brazil Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Gestational Diabetes Market

• 28.1. Middle East Gestational Diabetes Market Overview
• 28.2. Middle East Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Gestational Diabetes Market

• 29.1. Africa Gestational Diabetes Market Overview
• 29.2. Africa Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Gestational Diabetes Market Competitive Landscape And Company Profiles

• 30.1. Gestational Diabetes Market Competitive Landscape
• 30.2. Gestational Diabetes Market Company Profiles
  • 30.2.1. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis

31. Gestational Diabetes Market Other Major And Innovative Companies

• 31.1. Becton, Dickinson and Company
• 31.2. Boehringer Ingelheim GmbH
• 31.3. Dexcom Inc
• 31.4. Biocon Limited
• 31.5. LifeScan Inc
• 31.6. Ascensia Diabetes Care Holdings AG
• 31.7. Trividia Health Inc.
• 31.8. Nipro Diagnostics, Inc.
• 31.9. Sernova Corp.
• 31.10. ZyVersa Therapeutics, Inc.
• 31.11. Peptron Inc.
• 31.12. Roche Diabetes Care
• 31.13. DiabetOmics Inc
• 31.14. Merck & Co. Inc.
• 31.15. Medtronic plc

32. Global Gestational Diabetes Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Gestational Diabetes Market

34. Recent Developments In The Gestational Diabetes Market

35. Gestational Diabetes Market High Potential Countries, Segments and Strategies

• 35.1 Gestational Diabetes Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Gestational Diabetes Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Gestational Diabetes Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료